Bellicum unveils CAR-T aspirations with $55m Series C
This article was originally published in Scrip
Executive Summary
With another $55m in the bank, Bellicum Pharmaceuticals is sharing more details about its aspirations to enter the hot oncology field of chimeric antigen receptor (CAR)-T cell therapies.